statnews.com·May 14, 2026
CREATE Medicines has secured $122 million to advance its in vivo CAR-T cell therapy for autoimmune diseases, highlighting the expanding focus of biotech beyond cancer. Additionally, the Trump administration is seeking a new FDA commissioner, indicating potential political challenges for the agency's future direction.
CREATE Medicines' recent $122 million funding round to advance in vivo CAR-T therapies for autoimmune diseases represents a significant diversification in the application of cell therapies beyond oncology. This funding milestone signals a promising investment opportunity and a potential shift in the biotech landscape, emphasizing the expanding role of precision medicine in treating a broader range of conditions.